Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by ...

Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 trial planned for announcement in 2Q’25 - - Reported positive ...

Regeneron aims to advance cancer treatments through innovative research and partnerships while emphasizing the significance of their PD-1 inhibitor, Libtayo, in ongoing clinical trials.

Sanofi and Regeneron plan to file their cancer immunotherapy Libtayo (cemiplimab) in a new indication following supportive findings from a phase 2 trial in ... has shown a clinical benefit in ...

Dr Israel Lowy, senior vice president of translational and clinical sciences in ... and vice-chair of the Trial Steering Committee, commented: “Libtayo is an important advancement for patients ...

Palleon Pharmaceuticals has reported the outcomes from its Phase I/II study of E-602 along with programmed death (PD)-1 inhibitor cemiplimab (Libtayo ... Phase I/II clinical trial for E-602.

FibroGen said it believes that the mechanisms of action for both FG-3165 and FG-3175 have the potential to be synergistic with Libtayo, also known as cemiplimab, which could improve clinical outcomes.

including Libtayo, which is already a standard of care for advanced CSCC, and linvoseltamab, which has shown promise in clinical trials. The investigational uses of Libtayo, fianlimab, REGN7075 ...